GILD

166.4300.06%
AD

Andrew D. Dickinson

Executive VP & CFO

Mr. Andrew D. Dickinson, also known as Andy, is CEO & CFO of Tmunity Therapeutics, Inc. Mr. Dickinson has been a Director of Arcellx, Inc. since April 28, 2026. He is Director of CymaBay Therapeutics, Inc. from March 22, 2024. Mr. Dickinson was Non-Executive Non-Independent Director of Galapagos NV from March 26, 2024 until November 01, 2025. Mr. Dickinson serves as Director at Sutter Health since August 2021. He is the President, Treasurer and Director at Immunomedics, Inc. since October 23, 2020. Mr. Dickinson serves as Chief Financial Officer at Gilead Sciences, Inc. since November 1, 2019 and served as its Executive Vice President of Corporate Development & Strategy from June 04, 2018 to November 1, 2019. He serves as Executive Vice President at Gilead Sciences, Inc. since November 1, 2019. He sits on the Board of the Fosun Pharma. Mr. Dickinson serves as Senior Vice President of Corporate Development of Gilead Colorado, Inc. and served as its Vice President, General Counsel and Secretary since December 2, 2004. Earlier in his career, he served as General Counsel and Vice President of Corporate Development at Myogen Inc., which was acquired by Gilead in 2006. Mr. Dickinson led the acquisitions of Kite Pharma, Inc. and Cell Design Labs, Inc. Prior to joining Gilead, he served as Global Co-Head of Healthcare Investment Banking for Lazard. Prior to joining Myogen, Mr. Dickinson was a founding Partner of Kendall, Dickinson & Koenig. In addition, he previously served as a corporate and securities attorney at Cooley Godward LLP and Kirkland & Ellis LLP. Mr. Dickinson received a B.A. in molecular biology from the University of Colorado at Boulder from 1988 to 1993 and a J.D. from Loyola University of Chicago School of Law from 1993 to 1996.

Positions